Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2026-04-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2025年度独立董事述职报告—娄爱东
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from 哈药集团股份有限公司. It details the independent director's personal background, duties, attendance at board and committee meetings, oversight activities, communication with auditors and shareholders, and evaluation of company governance and compliance. The content focuses on the independent director's role and activities during the year, rather than presenting financial statements or audit results. It is a report on board/management information, specifically about the independent director's duties and oversight. There is no indication that this is an annual report (10-K), audit report (AR), or other financial report. The document is substantive and not a brief announcement or certification. Therefore, the most appropriate classification is Board/Management Information (MANG).
2026-04-22 Chinese
哈药集团股份有限公司董事及高级管理人员薪酬管理与履职评价制度（2026年4月）
Remuneration Information Classification · 95% confidence The document is titled '董事及高级管理人员薪酬管理与履职评价制度' which translates to 'Remuneration Management and Performance Evaluation System for Directors and Senior Management'. It details the principles, standards, evaluation procedures, and management mechanisms related to the compensation and performance assessment of the company's board members and senior executives. There are no financial statements, earnings data, or regulatory filings. The content focuses exclusively on remuneration policies and governance related to compensation. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-04-22 Chinese
哈药集团股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from 哈药集团股份有限公司 regarding abnormal stock price fluctuations over two consecutive trading days, with a cumulative price increase exceeding 20%. It includes the company's investigation and confirmation that no undisclosed material information exists that could explain the price movement. The document references compliance with Shanghai Stock Exchange trading rules and provides risk warnings to investors. The content is focused on stock trading abnormality disclosure rather than financial results, management changes, or other report types. The document length is short (1359 characters) and is an announcement about stock price abnormality, which fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about stock trading behavior and risk, not a financial report or other specific filing type.
2026-04-15 Chinese
哈药集团有限公司关于哈药集团股份有限公司股票交易异常波动询证函的回复
Regulatory Filings
2026-04-15 Chinese
哈药集团股份有限公司十届二十四次董事会决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a board resolution from 哈药集团股份有限公司 regarding internal management structure adjustments. It details the board meeting date, attendance, voting results, and the decision to split the audit and market supervision functions into two separate departments. There is no financial data, no mention of annual or quarterly reports, no audit report content, and no regulatory filings or certifications. The document is clearly about board/management information, specifically changes in internal management structure, which fits the Board/Management Information (MANG) category.
2026-03-09 Chinese
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the approval of a pharmaceutical product (注射用头孢噻肟钠) passing a consistency evaluation by the National Medical Products Administration. It details the drug specifications, approval notices, market impact, and risk warnings. The document is short (1151 characters) and serves as an official announcement about regulatory approval and its implications rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not a report publication announcement since it contains substantive content about the approval and impact. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about product approval and related business impact without fitting other specific categories like earnings, management changes, or capital updates.
2026-02-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.